FEIBA is associated with increased risk of thromboembolic events such as stroke, myocardial infarction, and deep vein thrombosis FDA Label.
Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aminocaproic acid | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Anti-inhibitor coagulant complex. |
| Alpha-1-proteinase inhibitor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Menadione | Menadione may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Tranexamic acid | Tranexamic acid may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Aprotinin | Aprotinin may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Hydrogen peroxide | Hydrogen peroxide may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Aminomethylbenzoic acid | Aminomethylbenzoic acid may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Camostat | Camostat may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Menadione bisulfite | Menadione bisulfite may increase the thrombogenic activities of Anti-inhibitor coagulant complex. |
| Monteplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Monteplase. |
| Lepirudin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin. |
| Bivalirudin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Bivalirudin. |
| Alteplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tenecteplase. |
| Abciximab | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Abciximab. |
| Drotrecogin alfa | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Drotrecogin alfa. |
| Streptokinase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Streptokinase. |
| Dicoumarol | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dicoumarol. |
| Argatroban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Argatroban. |
| Ardeparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ardeparin. |
| Phenindione | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Phenindione. |
| Fondaparinux | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Fondaparinux. |
| Warfarin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Warfarin. |
| Pentosan polysulfate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Pentosan polysulfate. |
| Phenprocoumon | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Phenprocoumon. |
| Dipyridamole | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dipyridamole. |
| Heparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Heparin. |
| Enoxaparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Enoxaparin. |
| Epoprostenol | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Epoprostenol. |
| Acenocoumarol | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Acenocoumarol. |
| 4-hydroxycoumarin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with 4-hydroxycoumarin. |
| Coumarin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Coumarin. |
| Ximelagatran | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ximelagatran. |
| Desmoteplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Desmoteplase. |
| Defibrotide | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Defibrotide. |
| Ancrod | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ancrod. |
| Beraprost | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Beraprost. |
| Prasugrel | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Prasugrel. |
| Rivaroxaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Rivaroxaban. |
| Sulodexide | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Sulodexide. |
| Idraparinux | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Idraparinux. |
| Cangrelor | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Cangrelor. |
| Astaxanthin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Astaxanthin. |
| Apixaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Apixaban. |
| Otamixaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Otamixaban. |
| Amediplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Amediplase. |
| Dabigatran etexilate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dabigatran etexilate. |
| Danaparoid | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Danaparoid. |
| Dalteparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dalteparin. |
| Tinzaparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tinzaparin. |
| (R)-warfarin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with (R)-warfarin. |
| Ethyl biscoumacetate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ethyl biscoumacetate. |
| Nadroparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Nadroparin. |
| Triflusal | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Triflusal. |
| Ticagrelor | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ticagrelor. |
| Ditazole | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Ditazole. |
| Vorapaxar | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Vorapaxar. |
| Edoxaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Edoxaban. |
| Sodium citrate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Sodium citrate. |
| Dextran | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dextran. |
| Bemiparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Bemiparin. |
| Parnaparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Parnaparin. |
| Desirudin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Desirudin. |
| Antithrombin Alfa | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Antithrombin Alfa. |
| Protein C | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Protein C. |
| Antithrombin III human | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Antithrombin III human. |
| Letaxaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Letaxaban. |
| Darexaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Darexaban. |
| Betrixaban | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Betrixaban. |
| Nafamostat | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Nafamostat. |
| Gabexate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Gabexate. |
| Fluindione | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Fluindione. |
| Protein S human | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Protein S human. |
| Brinase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Brinase. |
| Clorindione | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Clorindione. |
| Diphenadione | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Diphenadione. |
| Tioclomarol | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tioclomarol. |
| Melagatran | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Melagatran. |
| Saruplase | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Saruplase. |
| (S)-Warfarin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with (S)-Warfarin. |
| Tocopherylquinone | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tocopherylquinone. |
| Dabigatran | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dabigatran. |
| Semuloparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Semuloparin. |
| Troxerutin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Troxerutin. |
| Edetic acid | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Edetic acid. |
| Reviparin | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Reviparin. |
| Dermatan sulfate | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dermatan sulfate. |
| SR-123781A | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with SR-123781A. |
| Limaprost | The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Limaprost. |